| 著者 |
Shoji, Kota
Yoshida, Kenichi
Iyoda, Shinju
Ishikawa, Moe
Tanaka, Miu
Nobe, Michidai
Saito, Nijika
Shino, Yuto
Nannya, Yasuhito
Yamato, Genki
Tsujimoto, Shinichi
Shiba, Norio
Hayashi, Yasuhide
Shiozawa, Yusuke
Shiraishi, Yuichi
| en |
Shiraishi, Yuichi（Personal）
National Cancer Center Research Institute
|
Search repository
Chiba, Kenichi
| en |
Chiba, Kenichi（Personal）
National Cancer Center Research Institute
|
Search repository
Okada, Ai
Tanaka, Hiroko
Miyano, Satoru
Koga, Yuhki
Goto, Hiroaki
Terui, Kiminori
Ito, Etsuro
Kiyokawa, Nobutaka
| en |
Kiyokawa, Nobutaka（Personal）
National Research Institute for Child Health and Development
|
Search repository
Tomizawa, Daisuke
| en |
Tomizawa, Daisuke（Personal）
National Center for Child Health and Development
|
Search repository
Taga, Takashi
盛武, 浩
WEKO
28692
e-Rad_Researcher
40336300
| ja |
盛武, 浩
宮崎大学
|
| ja-Kana |
モリタケ, ヒロシ
|
| en |
Moritake, Hiroshi
University of Miyazaki
|
Search repository
Tawa, Akio
Takita, Junko
Nishikori, Momoko
Adachi, Souichi
Ogawa, Seishi
Matsuo, Hidemasa
|
|
内容記述 |
Driver mutations in KMT2A-rearranged (KMT2A-r) have been identified in acute myeloid leukemia (AML); however, age-related differences in their frequency and prognostic factors remain unclear. In this study, we report age-specific mutation profiles and outcomes in pediatric patients with KMT2A-r AML. In 239 cases of KMT2A-r AML, infants (<1 year, n = 59) showed a significantly higher event-free survival (EFS) and overall survival (OS) compared with children (≥1 year, n = 180). Conversely, in 538 cases of non-KMT2A-r AML, infants exhibited a significantly lower EFS and OS than children. KMT2A::MLLT4 was only detected in children with KMT2A-r AML and was associated with a poor prognosis. In KMT2A-r AML, mutations in signaling pathway genes, such as KRAS, were frequently detected in infants and children. However, the frequency of non-signaling pathway mutations was significantly higher in children. Moreover, non-signaling pathway mutations had no significant effect on the prognosis in infants and children, whereas KRAS mutations were associated with poor prognosis in both groups. Multivariate analysis identified older age, a high white blood cell count, KMT2A::MLLT4, and KRAS mutations as independent adverse prognostic factors for both EFS and OS. These age-specific mutation profiles suggest distinct disease mechanisms across age groups and may help refine risk stratification and treatment strategies for pediatric KMT2A-r AML. |
Fulltext (7.3 MB)
.png)
